INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 45 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $449,990 | +2899.9% | 472,000 | +2676.5% | 0.00% | – |
| Q1 2020 | $15,000 | -65.1% | 17,000 | -64.6% | 0.00% | – |
| Q2 2019 | $43,000 | -69.7% | 48,000 | -66.7% | 0.00% | -100.0% |
| Q1 2019 | $142,000 | -96.8% | 144,000 | -97.0% | 0.00% | -97.2% |
| Q4 2018 | $4,425,000 | +5431.2% | 4,806,000 | +5983.5% | 0.04% | +3500.0% |
| Q3 2018 | $80,000 | -96.6% | 79,000 | -97.0% | 0.00% | -92.3% |
| Q2 2018 | $2,342,000 | -80.8% | 2,665,000 | -82.4% | 0.01% | -80.3% |
| Q1 2018 | $12,226,000 | +582.3% | 15,137,000 | +580.6% | 0.07% | +725.0% |
| Q4 2017 | $1,792,000 | +10.3% | 2,224,000 | +6.8% | 0.01% | -27.3% |
| Q3 2017 | $1,624,000 | +22.6% | 2,082,000 | +41.3% | 0.01% | +57.1% |
| Q4 2016 | $1,325,000 | – | 1,473,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Man Investments (CH) AG | 3,300,000 | $2,640,000 | 2.48% |
| SYMPHONY ASSET MANAGEMENT LLC | 14,000,000 | $11,200,000 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 36,000,000 | $28,879,000 | 1.14% |
| Opera Trading Capital | 5,500,000 | $4,344,000 | 0.89% |
| MACKAY SHIELDS LLC | 17,789,000 | $14,221,000 | 0.52% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 24,415,000 | $19,539,000 | 0.37% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 6,000,000 | $4,918,000 | 0.37% |
| OAKTREE CAPITAL MANAGEMENT LP | 28,415,000 | $22,732,000 | 0.36% |
| GLG Partners LP | 8,700,000 | $6,960,000 | 0.33% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 42,285,000 | $33,828,000 | 0.28% |